Univariate results for 3-4 acute GvHD, 1-y TRM, and 5-y overall survival according to the number of HEL matches (HLA-A, B, C, and DRB1) and LEL (DRB3/4/5, DQ, and DP) mismatches scored in the GvH vector
| Number of HEL matches . | Number of LEL mismatches, % . | P value . | |||
|---|---|---|---|---|---|
| 0 mm . | 1 mm . | 2 mm . | >2 mm . | ||
| 3-4 Acute GvHD by d 100 | |||||
| 8/8 | 23 (19-27) | 29 (26-32) | 30 (26-34) | 32 (24-42) | .03 |
| 7/8 | 34 (28-42) | 34 (29-39) | 39 (33-44) | 43 (34-53) | .27 |
| 6/8 | 43 (33-52) | 42 (36-49) | 47 (41-54) | 40 (29-51) | .6 |
| TRM at 1 y | |||||
| 8/8 | 30 (26-35) | 36 (33-39) | 39 (36-44) | 39 (30-49) | .02 |
| 7/8 | 39 (32-46) | 45 (40-50) | 46 (41-51)% | 61 (51-70) | .005 |
| 6/8 | 59 (50-69)% | 48 (42-55) | 59 (52-65) | 67 (56-77) | .02 |
| Overall survival at 5 y | |||||
| 8/8 | 38 (34-43) | 37 (33-40) | 37 (33-41) | 37 (28-47) | .94 |
| 7/8 | 31 (24-38) | 33 (28-38) | 27 (22-32) | 25 (17-34) | .24 |
| 6/8 | 17 (10-25) | 26 (20-32) | 19 (14-24) | 18 (11-28) | .19 |
| Number of HEL matches . | Number of LEL mismatches, % . | P value . | |||
|---|---|---|---|---|---|
| 0 mm . | 1 mm . | 2 mm . | >2 mm . | ||
| 3-4 Acute GvHD by d 100 | |||||
| 8/8 | 23 (19-27) | 29 (26-32) | 30 (26-34) | 32 (24-42) | .03 |
| 7/8 | 34 (28-42) | 34 (29-39) | 39 (33-44) | 43 (34-53) | .27 |
| 6/8 | 43 (33-52) | 42 (36-49) | 47 (41-54) | 40 (29-51) | .6 |
| TRM at 1 y | |||||
| 8/8 | 30 (26-35) | 36 (33-39) | 39 (36-44) | 39 (30-49) | .02 |
| 7/8 | 39 (32-46) | 45 (40-50) | 46 (41-51)% | 61 (51-70) | .005 |
| 6/8 | 59 (50-69)% | 48 (42-55) | 59 (52-65) | 67 (56-77) | .02 |
| Overall survival at 5 y | |||||
| 8/8 | 38 (34-43) | 37 (33-40) | 37 (33-41) | 37 (28-47) | .94 |
| 7/8 | 31 (24-38) | 33 (28-38) | 27 (22-32) | 25 (17-34) | .24 |
| 6/8 | 17 (10-25) | 26 (20-32) | 19 (14-24) | 18 (11-28) | .19 |
Note: supplemental Table 1 shows the number of transplants in each category when scored in the GvH vector. Numbers in each group are for the survival model. Other models may have had fewer evaluable patients, as described in “Biostatistical methods.” Table shows incidence of the events (%) and CI.